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ABSTRACT
Aim: To assess the changes in body composition and leptin in the early post transplant 
period and to validate anthropometry in renal allograft recipients. 
Patients and Methods: Consecutive renal allograft recipients were assessed 
prospectively at baseline, 3 & 6 months post-transplant by anthropometry, DEXA and 
serum leptin levels. 
Results: 62 recipients (M:F=3:1, mean age 33.4±11.2 years), had a mean weight of 
52±10.1, 56.8±9.3 and 57.7±9.6 kg at baseline, 3 & 6 months, respectively (p<0.01). The 
mean body fat at baseline, 3 & 6 months were 11.1±5.7, 13.9±5.7 and 14.5±6.2 kg 
respectively (p<0.001). The fat increment in arms, legs and trunk were 37.4%, 31.6% and 
36.6% respectively. Skin fold thickness correlated well with fat (measured by DEXA) at 
all times (ICC=0.9, p<0.001). There was a 3.8% increase in lean body mass by 6 months 
(p<0.01) predominantly in legs. Anthropometry underestimated lean body mass. Total 
bone mineral content decreased from 1.92±0.34 to 1.85±0.31 kg (p=0.001) by 6 months, 
with significant reductions in spine (6.7%). The mean leptin levels at baseline, 3 and 6 
months were 5.3±7.9, 6.0±8.4 and 15.4±17.4ng/ml respectively (p<0.05). At all times, 
leptin levels positively correlated with total body and regional fat content (p<0.01). 
Conclusions: Post renal transplant, patients gain significant amount of weight, mostly 
due to accumulation of the fat, especially around arms & trunk .There is overall decrease 
in bone mineral content, predominantly in the spine. Anthropometric measurements for 
fat assessment are a reasonable substitute for DXA. Leptin levels correlate with body fat 
content.
INTRODUCTION
Weight gain is common after renal transplantation, influenced by improved appetite and a reversal of the 
uremic state.  Renal  transplant  patients are at  risk for  increased  weight,  centripetal  obesity and muscle 
atrophy because of their long-term glucocorticoid requirements.  Such changes in body composition are 
associated with an increased risk of cardiovascular complications, which is a major cause of morbidity and 
mortality  in  renal  transplantation  since  infective  complications  have  decreased  with  newer 
immunosuppressive  medication  and  therapeutic  drug  level  monitoring.  Body  composition  data  might 
provide insight in to the relation with outcome, survival and post transplant complications and it might 
affect approaches to nutritional therapy and to therapy in the field of physical activity.1
Various  techniques  are  available  to  measure  body  composition  such  as  isotope  dilution, 
anthropometry,  dual  energy  X-ray  absorptiometry  (DEXA)  and  multi-frequency  bioelectric  impedance 
analysis (MF-BIA). Anthropometry comprises of series of noninvasive & inexpensive method of estimating 
body composition. However, it is operator dependant. Traditional methods of estimating total body fat rely 
on assumption that the fat distribution and bone mineral content are constant. However,  in the patients 
undergoing  renal  transplantation  rapid  changes  in  body  composition  occur,  with  variations  in  fat 
distribution and bone mineral content.2 
Dual-energy x-ray absorptiometry (DEXA) has been shown to be an effective measure of body 
composition, has been considered a valid and reliable reference measure, and has advantage of showing a 
three-dimensional model of body composition. However, it is expensive and available at limited centres.3
Marked central adiposity is one of the main characteristics of metabolic syndrome and previously 
adipose  tissue  was  traditionally  considered  as  energy  storage  organ  but  currently  it  is  considered  as 
endocrine  organ  secreting  bioactive  peptides  called  “adipokines”  which  has  autocrine,  paracrine  and 
endocrine functions.  Leptin being one such hormone regulate caloric intake and energy balance.
Data from India is limited with respect  to body composition in the Post Transplant follow up 
period and the reliability of the anthropometry as compared to DEXA, which is expensive, and the role of 
leptin in the adiposity in renal transplant population. 
REVIEW OF LITERATURE
Human Body Composition:
The major component of the human body is water. The protein and fat components are relatively small, 
with the remainder being primarily bone and minerals. 
Figure 1. Human Body Composition
The non-fat component of body composition is termed fat free mass (FFM) and exists primarily as the chief 
structural and functional component of the human body. The FFM compartment consists in proportions of 
water (72%), protein (21%) and bone minerals (7%).
The fat compartment of the body is termed fat mass (FM) and will vary considerably between individuals 
in terms of absolute amount. Fat mass consists of 20% water and 80% adipose tissue and can, in obese 
persons be the largest component of the body. 
Fat percentage:
Table 1. Fat percentages for various body compositions
Subject Normal Overweight Obese
Adult Male 4-25% 25-30% >30%
Adult Female 12-29% 29-35% >35%
Comparison between lean and obese man:
Table 2. Body composition in lean and obese individuals
Content Lean man (70 kg) Obese man (100 kg)
Water 60% 47%
Protein 17% 13%
Fat 17% 35%
Remainder 6% 5%
There is a small amount of body protein available for energy, in the labile amino acid pool and muscle 
proteins during catabolism, (when the body is starving).
Carbohydrate is stored in the body typically as glycogen in the liver and in muscle and can vary between 
individuals ranging from approximately 500g in normal individuals to over a kilogram in trained athletes. 
Values also vary depending on body size and previous carbohydrate ingestion.
Elements:
The Mass of elements in a 70-kg person and the Volume of the purified elements are shown in the table 34.
Table 3. Volume and mass of elements in an average human
Element Mass(kg
) 
Volume(L
)
Element Mass(kg
) 
Volume(L
)
oxygen 43 37 potassium .140 .429
carbon 16 7.08 sulphur .140 .676
hydrogen 7.0 8.6 sodium .100 .103
nitrogen 1.8 2.05 chlorine .095 .063
calcium 1.0 0.645 magnesium .019 .010
phosphorus 0.78 0.429 iron .004 .005
Measurement of Body Composition:
Body composition measurements have been used to study how lean body mass (muscle, 
bone,  etc.)  and  body fat  change during health  and disease,  and have  been used as  a 
research  tool  in  studying  a  wide  variety  of  conditions,  including  metabolic  and 
neuromuscular disorders, obesity, and the effects of aging. Some usefulness has also been 
reported in differentiating people who are large due to high lean tissue mass from those 
with  high  fat  mass.  Finally,  there  has  been  some  research  into  the  use  of  body 
composition  calculations  to  make  risk  assessments  regarding  certain  diseases  and  to 
assess the effects of exercise and nutritional programs in some patient populations.
The exact measurement of body composition is not possible outside the examination of a 
person’s body after death. Given that limitation, the methods that are used to estimate 
body composition utilize predictive mathematical modeling along with body composition 
data collected with various techniques. All such techniques will present some variation 
and error based upon the underlying assumptions made while creating the formulae and 
their applicability on different populations. 
Body  composition  methods  are  based  upon  a  “compartment”  model  of  the  body, 
separating the body’s components into two, three, or four compartments. Most methods 
only calculate two compartments, which are lean body mass (bone, muscle, tendons, etc.) 
and fat  mass.  Dual  x-ray absorptiometry (DEXA),  also calculates  bone mass,  a  third 
compartment separate from lean body mass.  Some models can be combined to add a 
fourth  compartment,  body  water  content.  Several  methods  of  measuring  body 
composition  have  been  used  over  the  past  decade,  including  skin-fold  measurement, 
hydrostatic weighing, bioelectrical impedance, dual x-ray absorptiometry (DEXA), and 
air displacement.
Anthropometry:
Skin-fold  measurements,  also  called  anthropometry,  use  a  set  of  hand-held  calipers 
exerting  a  constant  known pressure to measure  the thickness  of various  skin-folds,  a 
portion of the skin pinched away from the body surface, at standard locations around the 
body. Either 3 or 7 skin-fold sites are used. Percentage body fat is calculated using the 
sum of the measurements. This technique is based upon the assumption that the thickness 
of subcutaneous fat reflects a constant proportion of total body fat. Several problems with 
this method are that the person making the measurements must be adequately skilled, and 
the calipers themselves must be accurately calibrated and have constant pressure. Finally, 
the  more  obese  a  person is  the  more  difficult  it  is  to  “pinch”  a  skin-fold  correctly, 
requiring a high level of technical skill to obtain accurate measurement.
Anthropometric Techniques:
Skin-fold thickness (SFT):- A skin-fold thickness (SFT) is defined as a measure of the double thickness of 
the epidermis,  underlying fascia  and subcutaneous adipose tissue.  There are two main assumptions in 
determining total body fat from skin-folds: 
1. That  there  is  a  constant  relationship between total  body fat  and  subcutaneous  fat  at  the  sites 
measured. The equation of Siri (1961) uses a two-compartment model, such that the human body 
consists  of  fat  mass  (FM) and  fat-free  mass  (FFM)  and  assumes  that  the  density  of  the  two 
compartments is constant between individuals at 0.90 g/cm3 for FM and 1.10 g/cm3 for FFM.
2. That the density of FFM is constant.
Collection  of  skin-fold  thickness  measurements  (SFT)  -  Skin-fold  measurements  also  assume  that 
subcutaneous fat is a reliable indicator of total body fat and that skin-fold compressibility remains constant. 
Durnin and Womersley (1974) validated the sum of four SFT (biceps, triceps, subscapular and suprailiac) 
against densitometry and devised sex and age dependent population-based linear regression equations to 
estimate total body density. All SFT measurements should be taken by the same trained member of staff 
from  identical  positions  on  each  subject,  following  the  World  Health  Organization  WHO  1987, 
anthropometric guidelines. Harpenden skin-fold calipers is used, with the subject in a standing position.
The four sites were as follows (Durnin and Womersley 1974):
1. Triceps: A mark is made at the mid-upper arm, midline of the posterior aspect of the arm over the 
triceps muscle, measured with the elbow bent at 90º, used for identifying the biceps and triceps 
SFT.  During the measurement,  the arm should be hanging  freely by the side,  palms inwards 
towards the thighs.
2. Biceps: Measured midline of the anterior aspect of the arm, over the biceps muscle, mid-point on 
the arm as described above.
3. Subscapular: Found just below and lateral to the bottom tip of the scapula, measured in a 45º 
angle.  Subjects  stand  with  their  arm  relaxed  by  their  side.  The  scapula  is  palpated  with  the 
fingertips to find the bottom of the bone and the SFT is then measured in the natural  crease. 
Subject’s shoulders are relaxed.
4. Suprailiac (waist): Found 1 cm above the anterior superior iliac spine (top of the hipbone) in the 
mid-axillary line (waistline).Measured horizontally with the subject breathing gently.
To take the measurement, the skin is gripped about 1cm above the selected site and the calipers applied 
below this site, the grip is removed and the measurement noted to the nearest 0.2mm. The calipers are then 
removed. This is repeated for 3 successive measurements, with the mean value calculated. 
Body density and percentage body fat is calculated using the equations of Durnin and Womersley (1974), 
for each side of the body, using the following equations:
Density (g/cm3) = c – m (log ΔS)
Where: D = Density, c and m = standard age and sex-specific coefficients
ΔS = Sum of all four skin-fold measurements (mm).
Once density is calculated, the Siri (1961) equation is used to estimate percentage body fat: Fat (%) = 
[(4.95 / D) – 4.5] x 100
Where: D = Density, 4.95 and 4.5 are the constants calculated by Siri (1961) using the assumptions on the 
density of FM and FFM5
Lean body mass is calculated by the following James Equation6
Lean Body Weight (men) = (1.10 x Weight(kg)) - 128 ( Weight2/(100 
x Height(m))2)
Lean Body Weight (women) = (1.07 x Weight(kg)) - 148 ( Weight2/
(100 x Height(m))2
Hydrostatic weighing:
Hydrostatic weighing, also known as underwater weighing, involves weighing a person 
when dry, then placing them into a tub or pool of water and measuring how much they 
weigh when totally submerged under water when the air in their lungs has been exhaled. 
Alternatively, the weight of the water displaced from the container being used may also 
be utilized. Using the knowledge that bone and muscle are more dense than water and 
will sink, as well as the fact that fat is less dense than water and floats, the difference 
between the dry weight measurement and the submerged weight provides information 
which than can be used to estimate fat mass. 
Limitations  of  this  method  include  complaints  about  it  being  uncomfortable  and 
cumbersome,  variability  in  the  ability  of  patients  to  fully  exhale,  variation  in 
measurement due to movement of the subject, and the aversion to submersion of some 
patients.  Additionally,  the  assumption  that  lean  body mass  density  is  constant  is  not 
accurate.  Athletic  individuals  frequently  have  higher  bone  and muscle  density,  while 
older  people  frequently  have  lower  bone  density,  leading  to  inaccurate  calculations 
depending upon the equations used.
Bioelectrical impedance:
Bioelectrical impedance is based upon the theory that different compartments conduct 
electricity better than others. For instance, fat acts as an electrical insulator and does not 
conduct  electricity  well,  while  muscle  conducts  electricity  quite  well.  This  method 
involves using two metal surfaces with a small electrical potential between them. When 
the  subject  comes  in  contact  with  the  plates  simultaneously,  electrical  current  flows 
through the subject.  The resistance to the current caused by the patient’s body is then 
used to calculate body composition data. 
Limitations  of  this  method  are  a  higher  standard  error  when compare  to  hydrostatic 
weighing and skin-fold measurement and dependency upon several variables which may 
be difficult to calculate accurately.
Dual Energy X-ray absorptiometry (DEXA):
Whole body dual energy x-ray absorptiometry (DEXA) is the only currently available 
measurement body composition that uses a three-compartment model. Lean body mass, 
fat mass, and bone mass are all estimated with this technique. This method is based on 
the principle  that  x-ray radiation is  absorbed differently by body minerals.  The more 
minerals contained in a material, the higher the absorption. Thus bone, which has a high 
mineral content, will absorb the radiation at a much higher rate than fat, which has a low 
mineral content. 
This method uses two different  low level  x-ray beams,  that  when passed through the 
body,  are  absorbed  at  varying  rates  by  the  different  compartments.  This  differential 
absorption of the x-rays is calculated to derive estimates of the three compartments. The 
radiation exposure when using this method has been reported to be very low. Limitations 
of this method include its inability to accurately measure body composition in extremely 
obese patients.
DEXA technology: 
A typical DEXA instrument consists of a padded table on which the patient lies and a 
movable C-arm with an X-ray tube below the patient and a detector above the patient. 
The X-ray tube generates photon beams of two different energy levels,  thus the term 
"dual-energy." A collimator below the table limits the scatter of the photons and directs 
them toward the area of interest. The difference in attenuation (reduction in intensity) of 
the  two  photon  beams  as  they  pass  through  body  tissue  of  variable  composition 
distinguishes bone from soft tissue and allows quantification of BMD. Denser and thicker 
tissue contains more electrons and allows fewer photons to pass through to the detector. 
A computer with specially designed proprietary software designed by each manufacturer 
completes the DXA "system."
Radiation exposure to the patient is very small, usually of a similar magnitude to daily 
background radiation. Radiation scatter beyond the edge of the DXA table is negligible. 
No shielding of the technologist or the room is necessary.  As a safety precaution, the 
technologist should not sit within three feet of the table edge while the patient is being 
scanned.
Figure 2. The DEXA apparatus
Plethysmography:
The use of body plethysmography, also know as air displacement plethysmography, is a 
technique  that  has  been  used  for  many  years  in  the  diagnosis  and  management  of 
respiratory diseases. Only recently has this technology been applied to the measurement 
of  body  composition.  Technically  similar  to  the  hydrostatic  method  but  using  air 
displacement instead of water displacement, this technique is relatively new. This method 
involves a patient entering a sealed container with a known volume of air. As the patient 
breathes through a tube connected to the air outside the device, the air displaced from the 
interior of the container is measured. This volume of air, in conjunction with body weight 
is used to calculate body composition. 
Limitations of this method are its limited availability,  and variability in measurements 
due to hydration status, variation in atmospheric pressure affecting air density, and body 
temperature of the subject.
Body fat distribution:
The  total  body  fat  is  distributed  between  visceral  and  nonvisceral 
(subcutaneous)  compartments.  Gonadal  steroids  play  a  major  role  in  the 
distribution of body fat. At the onset of puberty, men become more muscular 
and have less fat, whereas women increase their body fat relative to their 
muscle mass. These differences persist throughout life and are reflected in 
the typical male and female fat distribution.
With age, both gonadal steroid and growth hormone secretion decline, which 
may explain the rise in visceral fat with age in men. In women, higher serum 
testosterone  concentrations  are  usually  associated  with  increased  visceral 
fat. Thus, the decline in growth hormone and the loss of estrogen at the time 
of the menopause may explain the relatively rapid increase in visceral fat in 
postmenopausal women.
The distribution of body fat is important clinically. Visceral central adiposity is associated with a greater 
risk  of  metabolic  and  cardiovascular  disorders  including  insulin  resistance,  type  2  diabetes  mellitus, 
hypertension, and coronary heart disease (7-8)
Obesity and Renal Transplantation  : 
Weight gain is common after renal transplantation, which is influenced by improved appetite and a reversal 
of the uremic state. However, at least in the early post transplant period, the increase in body weight is 
mainly due to an increase in body fat mass. This phenomenon may be partly due to relatively high doses of 
steroids in the early period after renal transplantation, possibly mediated by their inhibiting effect on lipid 
peroxidation, but also appears to be related to physical inactivity.
Obesity is a major health issue in the Western world and now also in developing countries. Obesity also 
contributes to post transplantation cardiovascular morbidity, including NODAT9, which is a major cause of 
death in patients with a functioning transplant. It is also associated with DGF in the case of cadaver kidney 
transplants, and the exact cause is not known. 
Friedman et al10 investigated the prevalence,  demographics,  and trends in obesity at the time of kidney 
transplantation from a transplant database that included all kidney transplantations since 1987. Body mass 
indices  (BMIs)  at  the  time of  transplantation  were  stratified  by  demographic  categories  and  year  and 
compared with trends of obesity in the general population. They found that the majority (60%) of patients 
at the time of transplantation were overweight or obese; between 1987 and 2001, the proportion of obese 
transplant recipients increased by 116%.
Koolman et al11.  observed that the post transplantation weight gain is,  at least until  6 
months  after  transplantation,  predominantly  due  to  an  increase  in  fat  mass  and  the 
increase in fat mass was already evident within 3 months after transplantation. Although 
extremity fat mass also increased, the changes in truncal fat mass were most pronounced. 
Obesity increases the risk of surgery in general because patients are susceptible to delayed wound healing, 
difficulty  in  exposure of  the  operative  site,  and increased  incidences  of  ventral  hernias  and deep-vein 
thromboses.  However,  in patients undergoing organ  transplantation, there is  an additional  risk because 
these patients are on immunosuppression therapy, leading to increased risk for all types of infections, in 
particular,  wound  infections,  and  also  delayed  wound  healing.  Patients  on  sirolimus  therapy  have  an 
additional risk for wound infections, delayed healing, and incisional hernias. Therefore, obesity confers an 
additional risk to patients undergoing kidney transplantation.
There is a curious association of obesity and delayed graft function (DGF) which is defined as the need for 
dialysis therapy in the first week after kidney transplantation. DGF is important for a number of reasons; 
there  is  an increased  risk for  chronic rejection and decreased  graft  survival,  and it  can be difficult  to 
diagnose  acute  cellular  rejection  in  patients  who  have  prolonged  DGF.  DGF  also  leads  to  increased 
hospitalization and increased monitoring of the transplanted organ by means of noninvasive ultrasounds 
and graft biopsies. These issues lead to increased cost and risk for complications. The overall incidence of 
DGF  is  approximately  40%;  however,  with  the  use  of  perfusion  pumps  and  induction  therapy  with 
antibodies, the incidence of DGF has been Reduced.4 Data from the USRDS including more than 51,000 
patients receiving a kidney transplant found that a BMI greater than 36 kg/m2 was a major risk factor for 
DGF.
 
Howard et al12 compared 3 groups of patients (BMI < 25 kg/m2, BMI between 25 and 30 kg/m2, and BMI 
>35 kg/m2). They found that incidences of DGF were 26.7%, 31.0%, and 36%, respectively, which was not 
statistically significant. 
Series from St. Barnabas Medical Center, Livingston, NJ, found that the incidence of DGF was 24% versus 
13%  in  patients  with  a  BMI  greater  than  25  kg/m2  versus  those  with  a  BMI  less  than  25  kg/m2, 
respectively.13
Cardiovascular Morbidity after Kidney Transplantation
After kidney transplantation, patients experience increased cardiovascular morbidity and mortality caused 
by obesity,  hypertension, post transplantation hyperlipidemia,  and post transplantation diabetes mellitus 
(NODAT) as a result of steroids and calcineurin inhibitor medications. Enormous efforts are being directed 
to reduce cardiovascular morbidity by using steroid-reduction or steroid- withdrawal protocols. Some of the 
newer  medications,  such as  sirolimus,  also cause  a  greatly  increased  risk for  hyperlipidemia,  whereas 
steroid withdrawal should be balanced against a small, but definitive, risk for increased graft rejection.
Locsey et al14 studied dyslipidemia and obesity in 137 patients. Although only 21.89% of patients had 
BMIs greater than 25.1 kg/m2 on dialysis therapy, after transplantation the proportion increased to 36.49%. 
In  the group of patients treated with only cyclosporine A (CyA),  the incidence  of  hyperlipidemia  and 
hypertension  was  significantly  less  than  in  those  administered  a  combination  of  steroids  and  CyA  or 
steroids, CyA, and azathioprine. There was a definitive relationship between obesity and hyperlipidemia. 
They emphasized the importance of systematic control of lipid levels, diet with adequate carbohydrate and 
lipid content, and the necessity of avoiding obesity by selecting the optimal immunosuppressive treatment.
Baum  et  al15 prospectively  analyzed  506  renal  transplant  recipients  between  1983  and  1998.  In  all 
transplant recipients, coronary artery disease was the most common cause of death, and African-American 
transplant  recipients  had  the  shortest  graft  survival  and  greatest  percentage  of  deaths.  At  1  year  post 
transplantation, 39% of African-American transplant recipients were obese (BMI > 30 kg/m2), and odds 
ratios for NODAT were 3.5 and 5 times greater in nonwhite and obese transplant recipients, respectively. 
Multiple regression analysis confirmed the predominant independent effect of African-American race on 
weight gain; however,  hypercholesterolemia was independent of race or ethnicity and was predicted by 
CyA treatment and NODAT.
Obesity and New onset Diabetes after transplantation (NODAT):
Kasiske et al16 analyzed data from the USRDS with regard to 11,659 Medicare beneficiaries who received 
their first kidney transplant in 1996 to 2000. Cumulative incidences of NODAT were 9.1%, 16.0%, and 
24.0% at 3, 12, and 36 months post transplantation, respectively. Risk factors for NODAT included age, 
African-American  race,  Hispanic ethnicity,  male donor,  increasing HLA mismatches,  hepatitis  C virus 
infection, BMI of 30 kg/m2 or greater, and use of tacrolimus as the initial maintenance immunosuppressive 
medication. 
Obesity and Long-Term Outcomes after Kidney Transplantation
Meier-Kriesche et al17 retrospectively analyzed 51,927 primary adult renal transplantations registered in the 
USRDS. They categorized BMI values into 11 subgroups: less than 18 kg/m2, from 18 to 36 kg/m2 at 2-
unit  increments,  and greater  than  36  kg/m2.  Primary  study endpoints  were  graft  and patient  survival. 
Secondary study endpoints were death-censored graft survival, chronic allograft failure, DGF, and acute 
rejection. Using a variety of statistical methods, they found that extremes of very high and very low BMIs 
were associated with significantly worse patient and graft survival, but not with acute rejection. Elevated 
BMI also was associated with an increased risk for DGF, whereas lower BMI was significantly protective.
Yamamoto et al,18 from Albany Medical Center, analyzed patient and graft survival in recipients of paired 
kidneys with similar preservation technique and surgical personnel. Between June1992 and August 1999, a 
total of 28 kidneys were transplanted into 1 obese and 1 nonobese recipient. DGF (7.1% versus 10.7%), 
acute rejection (39.3% versus 35.7%), and graft survival at 1 year were similar in the obese and nonobese 
recipient groups. Patient survival was similar at 1, 3, and 5 years in both groups. However, a trend toward 
decreased medium-term graft survival, which reached significance at 5 years, was observed in the obese 
group. Furthermore, mean serum creatinine level at 1 year was greater in the obese group (2.0 mg/dL [177 
µmol/L]) compared with the nonobese group (1.4 mg/dL [124µmol/L]). 
Meier-Kriesche  et  al13,  from St Barnabas Medical  Center,  Livingston,  NJ, studied the effect  of a BMI 
greater than 25 kg/m2 on long term renal transplantation outcome in 405 patients from 1990 to 1997. BMI 
greater than 25 kg/m2 were isolated as an independent risk factor for both decreased graft survival and 
patient survival (relative risk, 2.0 for each). Cadaveric donor status, acute rejection, and use of azathioprine 
versus mycophenolate mofetil were the only other significant risk factors.
Modlin et al19, from the Cleveland Clinic, compared 127 obese(BMI >30 kg/m2) patients with a matched 
nonobese control group (BMI < 27 kg/m2) of 127 transplant recipients with similar demographics. There 
were  no  significant  differences  between  groups  according  to  donor  source,  recipient  race  or  sex,  re-
transplantation,  transplant  percentage  of  reactive  antibodies,  cause  of  renal  failure,  or  hypertension. 
Significantly  more obese  patients  had  a pre-transplantation history of  angina  or  myocardial  infarction. 
Mean follow-up was approximately 58.9 ± 40 months. Nonobese patients showed a significantly greater 
patient survival rate (89% versus 67%) at 5 years and only approximately half the number of deaths (25 
versus 46 deaths) during the study. However, there were no significant differences between groups in DGF, 
acute rejection, chronic rejection, length of hospital stay,  surgical  blood loss, or mean serum creatinine 
level up to 5 years. Obese patients experienced a significantly greater incidence of NODAT (12% versus 
2%).
Johnson et al20 evaluated the effect of obesity on renal transplantation in a single Australian center between 
1994 and 2000. Of 493 patients who underwent transplantation, 59 patients (12%) were obese (BMI > 30 
kg/m2).  Obese patients were more likely to experience superficial  wound breakdown,  complete wound 
dehiscence, and wound infections. There were no significant differences between the 2 groups with respect 
to surgery duration, postoperative complications, hospitalization, DGF, or acute rejection episodes. Five-
year actuarial survival rates were similar between the 2 groups with respect to graft and patient survival. 
Howard et al21,  from the University of Florida College of Medicine, reviewed patients receiving a kidney 
transplant between 1990 and 1999 and grouped according to BMI. Group 1 had a BMI less than 25 kg/m2 
(n =457); group 2, BMI of 25 or greater and less than 30 kg/m2 (n = 278); and group 3, BMI of 35kg/m2 or 
greater (n = 98). Cadaveric graft survival rates at 2 years were 85% for group 1, 88% for group 2, and 85% 
for group 3. Cadaveric patient survival rates at 2 years were 92% for group 1, 91% for group 2, and 94% 
for group 3. There were no differences in technical losses or post transplantation wound complications. 
However,  group  3 patients  had  a  greater  incidence  of  NODAT.  They concluded  that  obese  transplant 
recipients have outcomes similar to nonobese patients.
Merion et al22, from the University of Michigan Medical School, examined the influence of preexisting 
obesity (weight >120% of ideal body weight) on outcome after renal transplantation. Among 263 CyA-
treated recipients of renal allografts, 223 patients (85%) were nonobese and 40 patients (15%) were obese 
before transplantation. Obese and nonobese transplant recipients were similar with regard to demographics, 
incidence of diabetes, and pre-transplantation serum cholesterol levels. There was a significantly greater 
incidence of wound infections in obese transplant recipients; other complications occurred with a similar 
incidence. There was no difference in incidence or number of rejection episodes; patient survival rates were 
93% for  nonobese  patients  at  3  years  and 90.5%, which was not  significant,  for  obese patients.  Graft 
survival also was similar between the groups.
Drafts et al23 reviewed their experience with living donor and cadaver transplantation in the current decade, 
focusing specifically on the impact of obesity on transplant outcome. Preoperative BMI was calculated for 
all  adult  renal  transplant  recipients  between 1990 and 1995 and used to classify patients as nonobese, 
moderately obese, or morbidly obese. The effect of degree of obesity on early and late outcomes after renal 
transplantation was examined. Three hundred thirty-three transplant recipients had a pre-transplantation
BMI less than 30 kg/m2 (normal or mild obesity), 68 patients had a BMI of 30 to 40 kg/m2 (moderate 
obesity),  and 7 patients had a BMI greater  than 40 kg/m2 (morbid obesity).  There was no correlation 
between obesity and other demographic factors. Wound infections and DGF occurred more commonly in 
moderately and morbidly obese patients than in other cadaver donor recipients. Obese patients gained more 
weight  after  surgery  and  were  administered  lower  CyA  doses  per  kilogram.  However,  there  was  no 
significant correlation between obesity and graft survival for either cadaver or living donor transplants.
Treatment of Obesity after Kidney Transplantation:
Obesity continues to be a problem after successful kidney transplantation; however, this has not received as 
much attention as obesity at the time of listing for a kidney transplant. 
Dietary Control
Lopes et al24,  from Spain, examined the nutritional status of 23 renal  transplant  recipients with a BMI 
greater  than 27 kg/m2,  hyperlipidemia,  and stable renal  function before  and after  6  months of dietary 
intervention with the American Heart Association Step One pattern. After the dietary intervention, lipid 
profiles improved in all patients, with a decrease in mean total cholesterol level (237 versus 224 mg/dL 
[6.13 versus 5.79 mmol/L];(P <0.05), which was greater in men. Also, LDL cholesterol level was reduced 
in male patients (156 versus 136 mg/dL [4.03 versus3.52 mmol/L];(  P<0.05), whereas in women, LDL 
cholesterol levels remained unaltered. HDL cholesterol and triglyceride values were not affected in men or 
women by the dietary treatment. The reduction in serum cholesterol level correlated inversely with initial 
triceps skin-fold value and was lower in patients with a BMI greater than 30 kg/m2 (5.7% versus 2.8%; P 
=NS). They concluded that obesity and hyperlipidemia after renal  transplantation may be improved by 
dietary intervention. 
Patel25, from The Royal Hospitals, England, examined the effect of early intensive dietary intervention and 
follow-up on weight gains in new renal transplant recipients. Group A was studied prospectively, and group 
B was studied retrospectively during 1 year post transplantation. Group A consisted of 11 patients (9 men, 
2 women) who underwent transplantation consecutively during 2 months, with a mean age of 39 years. 
Group B consisted of 22 patients (14 men, 8 women) who had undergone transplantation consecutively 4 
years before the study, with a mean age of 40 years. Both groups had functioning grafts and similar triple 
immunosuppressive  therapy  (prednisolone,  CyA,  and  azathioprine).  Group  A  received  intensive 
individualized dietary advice in stages, with regular follow-up for the first 4 months post transplantation, 
whereas group B did not receive dietary advice. Patel found that patients in group A showed significantly 
lower weight gains compared with group B at 4 months and 1 year. At 1 year, group A had a mean weight 
gain of 5.5 kg/patient compared with 11.8 kg/patient in group B. Intensive dietary advice is an effective 
tool to prevent weight gain in kidney transplant recipients. This may take the form of a specialized diet, 
such as the American Heart Association Step One, or another specific diet plan suggested by a qualified 
dietician.
Surgery
Bariatric  surgery before  or  after  kidney transplantation has  been  reported in  the form of  case  reports. 
Marterre et al 26, from the University of Cincinnati Medical Center, performed Roux-en-Y gastric bypass in 
3 morbidly obese (200% to 260% of ideal body weight) patients 6 to 8 years after kidney transplantation. 
Both patients who developed NODAT had complete resolution within 9 months after bypass surgery. On 
average, patients required 3 fewer hypertension medications after surgery;  2 of the 3 patients were off 
medication, with significant improvement in hyperlipidemia.
Steroid Withdrawal
Modern immunosuppressive regimens have succeeded in reducing the risk for acute rejection; however, 
long-term  dangers  of  cardiovascular  disease  and  other  post  transplantation  complications  of 
immunosuppressive therapy persist. Long-term use of steroids is linked with a well known pattern of side 
effects on skin, bone, and the cardiovascular system in renal transplant recipients. Hyperlipidemia, which is 
increased in patients administered steroids, is one of the most important risk factors for cardiovascular 
diseases27. Steroid withdrawal has been shown to definitely reduce cholesterol and LDL levels in recipients 
of solid-organ transplants, and there is a trend toward reduction of obesity28. Steroid withdrawal will lead to 
a reduction in cardiovascular morbidity; however, this has to be balanced against the small increased risk 
for acute rejection.
Psychotherapeutic Programs
Weight gain and its prevention is a concern in a majority of the population. However, weight gain among 
hemodialysis patients and transplant recipients is particularly worrisome because studies have suggested a 
direct correlation between obesity, quality of life, and compliance behavior. Obesity has been addressed 
successfully  by  using  behavioral  modification,  a  combination  of  nutritional  education  and  supportive 
counseling  among  patients  with  diabetes.  Melin  et  al29  associated  the  most  successful  outcomes  with 
continuous feedback  and positive re-enforcement  from the counselor,  along with realistic  goal  setting. 
Other programs have successfully combined physical activity regimens, counseling, and nutritional advice 
among general population cohorts.
Leptin:
Leptin  was  discovered  as  a  result  of  studies  of  ob/ob  mice,  a  strain  of 
hyperphagic  obese  mice  that  were  known  to  lose  weight  when  their 
circulation was attached to normal mice (parabiosis) 30. Subsequent studies 
revealed that ob/ob mice had a mutation that results in inability to produce a 
protein,  first  called  the  ob  protein  and  later  leptin  that  regulates  food 
intake31. In addition to being very obese, these mice grew poorly and had 
infertility  due  to  gonadal  hypofunction.  Administration  of  leptin  to  these 
animals  resulted  in  a  marked  decrease  in  food  intake,  weight  loss,  and 
improved  growth  32.  Other  obese  mice,  diabetic  (db/db)  mice  and  fatty 
(Zucker)  rats  have genetic  defects  in  the leptin  receptor  33.  Db mice are 
phenotypically identical to ob mice.
In humans, the leptin gene is located on chromosome 7q32 and consists of 
three exons and two introns that span 20 kilobases (kb) of DNA. The mouse 
and  human ob  genes  have  84  percent  homology.  The  gene  codes  for  a 
secreted protein of 167 amino acids.
Mechanism of Action of Leptin : 
Leptin is a member of the cytokine family, and its receptor is a member of 
the gp130 group of cytokine receptors. There are at least five forms of the 
leptin  receptor  34.  The  most  widely  distributed  is  the  short  form  of  the 
receptor, which is present in most tissues and may serve to transport leptin 
into the brain. The long form of the receptor is located in areas where leptin 
is  thought  to  act,  including  hypothalamic  nuclei.  There  may  also  be  a 
circulating form of the leptin receptor that binds leptin.
The  signaling  system  on  the  intracellular  portion  of  the  leptin  receptor 
belongs to the janus kinase signal transduction and translation system (JAK 
STAT). It is the Stat-3 form of the STAT system that is thought to carry out 
the intracellular signaling 35. A counter-regulatory system that inhibits leptin 
and cytokine action exists  in the suppressors of  cytokine signaling, which 
occur  in  at  least  three different forms.  Parenteral  administration of  leptin 
increases mRNA levels for one form of this suppressor in the hypothalamus, 
liver, and small intestine, which may explain the occurrence of resistance to 
the action of leptin 36.
Circulating factors that bind leptin might also contribute to leptin resistance. 
In one study, C-reactive protein was identified as a circulating factor that 
binds to leptin, impairs its signaling, and attenuates its physiologic effects (in 
cultured  cells  and  an  ob/ob  mouse  model)  37.  In  addition,  physiologic 
concentrations of leptin stimulated C-reactive protein expression in vitro.
Food intake:  
Food intake is reduced by systemic leptin administration in normal-weight 
experimental  animals,  but the response decreases as the animals become 
obese. However, when leptin is injected into the ventricular system of the 
brain of obese animals, they remain responsive 38. Since leptin is transported 
across  the  blood-brain  barrier  to  act  within  the  brain,  the  processes 
controlling the entrance of leptin into the brain are pivotal determinants of its 
action on food intake 39.
Leptin decreases food intake in several  ways. It decreases the content of 
neuropeptide  Y  (NPY)  mRNA (40-41) and  it  increases  the  content  of 
proopiomelanocortin  (POMC)  mRNA  in  the  arcuate  nucleus  of  the 
hypothalamus42. NPY is one of the most potent stimulators of food intake 40, 
and  alpha-melanocyte-stimulating  hormone  (alpha-MSH),  produced  by 
cleavage  of  POMC,  inhibits  food  intake.  Thus,  leptin  acts  in  the  arcuate 
nucleus to reduce food intake in two ways, decreasing NPY and increasing 
alpha-MSH.
The importance of these effects is illustrated by the following observations. 
Leptin-deficient ob mice that are also deficient in neuropeptide Y are less 
obese  than  ob  mice  in  which  neuropeptide  Y  production  is  normal  43. 
Furthermore, mice lacking POMC-derived peptides are obese and lose weight 
when treated with alpha-MSH44.
Prothrombotic effect:
Leptin also may have a prothrombotic effect. Leptin-deficient mice form an 
occlusive thrombus more slowly than wild-type mice, a change reversed by 
leptin replacement 45. 
This effect appears to be mediated through the platelet leptin receptor.
Bone formation:
Data on the effect of leptin on bone metabolism are conflicting. In obese 
mouse  models  deficient  in  leptin  (ob/ob)  or  its  receptor  (db/db),  bone 
formation and bone mass have been reported to be increased 46, decreased 
47, or variable depending upon the bone site48. It appears that leptin's effects 
on energy balance and bone occur at the level of the hypothalamus, although 
the pathways appear to be distinct 46.
Data  in  the  human  are  also  inconclusive,  as  observational  studies  have 
reported both a positive (48, 49, 50) and negative (51, 52, 53, 54) association between 
serum  leptin  concentrations  and  bone  density.  However,  in  a  study  of 
exogenous leptin  administration  in  women with  hypothalamic  amenorrhea 
(who are leptin-deficient55, an Increase In Markers Of Bone Formation Was 
Observed56. 
Biology of Leptin:
Leptin is produced primarily in fat cells, and also in the placenta and probably 
in  the stomach.  Large fat cells  produce more leptin than small  ones and 
serum leptin concentrations are highly correlated with body fat content in 
newborn infants, children, and adults  (57,  58). Leptin mRNA and secretion by 
adipocytes declines rapidly during starvation. These processes are stimulated 
by insulin, glucocorticoids and tumor necrosis factor-alpha, another product 
of adipocytes. These observations suggest that leptin signals the brain about 
the quantity of stored fat.
Leptin production in humans:
 Features of leptin production in humans other than the correlation with body 
fat content include:
1. Serum leptin concentrations increase with progressive obesity. 
The concentrations are higher in women than in men, for any measure 
of obesity (59, 60), and they decrease with age in both women and men 
61.  Pregnant  women  have  higher  serum  leptin  concentrations  than 
nonpregnant  women  62.  Breastfeeding  may reduce  the  risk  of  child 
obesity 63, and leptin could possibly play a role, as it is produced in the 
breast  and  is  present  in  milk  (64,  65).  Serum  leptin  concentrations 
increase during childhood, with the highest concentrations in children 
who  gain  the  most  weight;  higher  serum leptin  concentrations  are 
associated with an earlier onset of puberty 66. The potential importance 
of leptin in this setting is illustrated by the observation that mice and 
rats deficient in leptin fail to undergo pubertal development, while the 
administration of leptin to such animals results in pubertal onset  67. 
Serum leptin concentrations are similar in black and white children of 
similar  body  composition  (68,  69).  The  concentrations  are  similar  in 
normal subjects and patients with type 2 diabetes mellitus of the same 
weight; chronic endogenous hyperinsulinemia does not increase leptin 
secretion, although infusion of insulin and glucose for two days does 70. 
2. There is  a  diurnal  rhythm of serum leptin concentrations,  the 
values being 20 to 40 percent higher in the middle of the night as 
compared with daytime (70,71). The peak shifts in parallel with shifts in 
the timing of meals  72. In human beings, plasma leptin is related to 
blood  pressure  levels  in  both  normotensive  73 and  hypertensive 
subjects (74, 75). 
3. Leptin  production  is  strongly  influenced  by  nutritional  state. 
Overeating increases serum leptin concentrations by nearly 40 percent 
within  12  hours,  long  before  any  changes  in  body  fat  stores. 
Conversely, in both normal-weight and obese subjects, fasting reduces 
serum leptin concentrations by 60 to 70 percent in 48 hours 76.
CLINICAL STUDIES 
Genetic disorders:
Leptin deficiency: 
Congenital leptin deficiency due to a mutation in the leptin gene, produces 
massive obesity,  similar to that seen in rodent models that lack leptin or 
leptin  receptor  (77,  78).  Early-onset  obesity  and  profound  hyperphagia  are 
characteristic  of  these  individuals,  as  are  hyperinsulinemia  and  advanced 
bone age (79, 80, 81). Hypogonadotrophic hypogonadism occurs in some patients 
80.
Serum leptin  levels  were  significantly  lower  in  heterozygous  members  of 
these families than would be expected from their percent body fat. However, 
these heterozygotes had normal thyroid function, appropriate gonadotropin 
levels  and  normal  secondary  sexual  characteristics,  including  menstrual 
cycles. Leptin deficiency also reduces TSH pulsatility.
Food intake was dramatically  reduced when three leptin deficient children 
were treated with leptin 79. Pubertal development was seen in one child, and 
serum concentrations of free thyroxine and TSH increased into the normal 
range.
In  a  second  study,  leptin  replacement  therapy  for  18  months  in  three 
morbidly  obese  homozygous  leptin-deficient  adults  resulted  in  dramatic 
weight loss, and resolution of type 2 diabetes and hypogonadism  81. There 
was an initial decrease in food intake (energy intake) which reached a nadir 
at four to six months, but which then gradually returned towards baseline, 
but this was offset by a progressive increase in physical activity.
Leptin receptor deficiency: 
Human obesity resulting from a mutation in the leptin receptor (LEPR) has 
been described  (82,  83).  In  one report,  8  of  300 subjects  (3  percent)  with 
severe, early-onset obesity had nonsense or missense LEPR mutations (six 
probands were from consanguineous families). In addition to severe obesity 
and hyperphagia, other characteristics of affected patients included:
1. Alterations in immune function (decrease in the absolute CD4+ T-cell 
count with compensatory increase in the CD19+ B-cell count). 
2. Normal linear growth, but reduced adult height as adults (due to lack 
of pubertal growth spurt). 
3. Delayed puberty due to hypogonadotropic hypogonadism. 
4. Increased serum leptin concentrations (consistent with their elevated 
fat mass, but not disproportionately increased, suggesting that serum 
leptin levels are not a useful marker for LEPR deficiency). 
5. Less  severe  clinical  features  when  compared  to  patients  with 
congenital leptin deficiency (less hyperphagia, lower BMI, and lower 
percentage body fat). 
Obesity: 
Most  obese  people,  however,  are  not  leptin  deficient,  and  serum  leptin 
concentrations are directly related to their amount of body fat. In several 
surveys of obese subjects, no mutations in the leptin gene were detected (84, 
85). Given the high serum leptin concentrations and apparent leptin resistance 
in obese subjects (59, 60) little response to exogenous leptin might be expected. 
However, in a study of the effect of recombinant leptin (0.01, 0.03, 0.1, or 
0.3 mg/kg per day) or placebo in normal-weight subjects for four weeks and 
obese  subjects  for  24  weeks,  there  was  a  very  modest  dose-dependent 
decrease in weight in both groups 86. After weight loss, leptin administration 
prevents  the  decline  in  metabolic  rate  and  circulating  concentrations  of 
thyroid hormone 67.
Hypothalamic amenorrhea:
Leptin  administration  for  the  relative  leptin  deficiency  in  women  with 
functional hypothalamic amenorrhea (due to weight loss, excessive exercise, 
or an eating disorder)  (55, 56) may improve function of the reproductive axis 
(increased serum LH concentrations and pulsatility) as well  as the thyroid 
and growth hormone axes (87, 88).
Lipodystrophy:
Leptin-replacement therapy is  effective  in  patients  with  lipodystrophy and 
leptin deficiency. 
Immune Function:
Leptin deficient individuals have a decrease in CD4 cells and reduced T-cell 
production 79 that are consistent with their higher rates of childhood infection 
80 Leptin replacement leads to a switch from secretion of predominantly Th2 
cytokines to Th1 cytokines 79.
AIM
1. To assess the changes in body composition and leptin in the early post transplant period in renal 
allograft recipients
2. To validate anthropometric measurements using DEXA in renal allograft recipients. 
PATI  ENTS AND METHODS  
Design and Location: 
This prospective study was conducted at the Department of Nephrology, Christian Medical College (CMC), 
Vellore. 
Inclusion Criteria:
a) Renal allograft recipients with 6 months of follow-up.
b) DEXA scans and serum samples for Leptin analysis available at baseline, 3rd and 6 months.
Exclusion Criteria:
a) Renal allograft recipients with less than 6 months of follow-up.
b) DEXA scans or serum samples for Leptin not available at any of the point in the study period.
Duration: 
Patients  who underwent  renal  transplantation  at  CMC, Vellore  between May 2006 to  Feb  2007 were 
included and followed up till August 2007
Methodology: 
Renal allograft recipients, on inclusion, underwent evaluation at baseline, 3 months and at 6 months after 
their transplant operation. All patients underwent anthropometric evaluation, whole body DEXA scans and 
Serum leptin level estimation at these time points. Clinical details were noted from the patient follow up. 
Measurements:
1. Anthropometry: 
i. Height and Weight – Height and weight of patients were measured on height and weighing 
scales, standardized to the rules of Department of Legal Metrology of the Government of 
India. Anthropometric calculations were based on the following formulae:
1. Lean Body Weight in Kg = LBW=[(1.10-(0.03 X sex] X (weight)-{[128 + (sex X 
20 )] X [(weight/height)2] 
2. Body mass index in Kg/m2 =BMI = Weight in Kg / (Height in ms)2
ii. Skin Fold Thickness (SFT): SFT were measured using Harpenden's calipers and estimation 
of body fat done by method of Durnin and Wormesley as detailed below. The four sites were 
as follows (Durnin and Womersley 1974):
5. Triceps: A mark is made at the mid-upper arm, midline of the posterior aspect of the 
arm  over  the  triceps  muscle,  measured  with  the  elbow  bent  at  90º,  used  for 
identifying the biceps and triceps SFT. During the measurement, the arm should be 
hanging freely by the side, palms inwards towards the thighs.
6. Biceps: Measured midline of the anterior aspect of the arm, over the biceps muscle, 
mid-point on the arm as described above. 
7. Subscapular: Found just below and lateral to the bottom tip of the scapula, measured 
in a 45º angle. Subjects stand with their arm relaxed by their side. The scapula is 
palpated  with the fingertips  to  find the bottom of  the bone and  the SFT is  then 
measured in the natural crease. Subject’s shoulders are relaxed. 
8. Suprailiac (waist): Found 1 cm above the anterior superior iliac spine (top of the 
hipbone) in the mid-axillary line (waistline).Measured horizontally with the subject 
breathing gently. 
To take  the measurement,  the skin is  gripped  about  1cm above the  selected  site  and the 
calipers applied below this site, the grip is removed and the measurement noted to the nearest 
0.2mm. The calipers are then removed. This is repeated for 3 successive measurements, with 
the mean value calculated. 
Body  density  and  percentage  body  fat  is  calculated  using  the  equations  of  Durnin  and 
Womersley (1974), for each side of the body, using the following equations: 
Density (g/cm3) = c – m (log ΔS)
Where: D = Density, c and m = standard age and sex-specific coefficients 
ΔS = Sum of all four skin-fold measurements (mm).
Once density is calculated, the Siri (1961) equation is used to estimate percentage body fat: 
Fat (%) = [(4.95 / D) – 4.5] x 100
Where:  D = Density,  4.95  and  4.5  are  the  constants  calculated  by  Siri  (1961)  using  the 
assumptions on the density of FM and FFM5
2. DEXA: Whole Body scan was performed using HOLOGIC DEXA apparatus for whole and regional 
body fat, bone mineral content and lean body mass. 
3. Serum Leptin: Fasting serum samples for the Leptin were drawn and stored at -70º centigrade. All 
Serum samples for Leptin were analyzed at 6 months by Leptin (Sandwich) ELISA. (DRG Instruments 
GmbH, Germany).
Statistical Analysis: 
1. Measures of central tendency and distribution – Mean ± standard deviations were used for 
normally distributed data and median & range (min – max) was used for skewed data to avoid 
the outlier effect. 
2. An intra-class correlation coefficient (one way random) was calculated for the 
Anthropometry and DEXA measurements and their significance was determined. Scatter plots 
were used for graphical representation of the same. 
3. Bias and precision were calculated based on the following definitions and graphically 
demonstrated using Bland -Altman analysis plots
i. Bias  = Mean difference (x – y)
ii. Precision – 2 Std. deviation of Bias = 2  X  S.D (x – y)
x, y – variables.
RESULTS
Patient Profile: It is a prospective study from May 2006 to February 2007. 73 patients underwent renal 
allograft transplantation of which three patients had less than 6 months follow up period, 7 patients had not 
performed one of the 3 sets of DEXA scans and 1 patient was excluded from the study in view of moribund 
obesity. Statistical analysis was performed on 62 patients.
Demographic Data: 
Among 62 patients, 45 were males (72.58%) 
The mean age:
• Male-32.31±11.20 years
• Female-36.29±8.91 years
Body Weight:
Table 4. Temporal Profile of Weight
Weight 
(Kg)
Baseline 
(mean±SD)
3 months 
(mean±SD)
6 months 
(mean±SD)
Male (n=45) 54.51 ± 10.00 58.72 ± 9.07 58.97 ± 9.58
Female (n=17) 47.16 ± 8.91 51.94 ± 8.33 54.62 ± 9.18
Total (n=62) 52.49 ± 10.19 56.86 ± 9.32 57.78 ± 9.60
Figure 3. Temporal profile of body weight
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Body Mass Index: 
Nearly half of the study population (45.2%) were underweight (BMI <18.5) at the entry of study, which 
reduced to 21% by3 months and 17.7% by the end of 6 months the distribution of normal weight (BMI- 
18.5-24.9) and over weight(BMI- 25-29.9) category as shown in the  table below
Table 5. Body Mass Index 
BMI baseline 3 months 6 months
<18.5 28(45.2%) 13(21.0%) 11(17.7%)
18.5-24.9 30(48.4%) 41(66.1%) 40(64.5%)
25-29.9 4(6.5%) 8(12.9%) 11(17.7%)
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Figure 4. Temporal Profile of Body Mass Index
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Table 6. Body Mass Index profile in Males and Females.
BMI Gender Baseline 3 months 6 months
<18.5 Total 28(45.2%) 13(21.0%) 11(17.7%)
Male 20(44.4%)      9(20%)      9(20%)
Female   8(47.0%)   4(23.5%)   2(11.8%)
18.5-24.9 Total 30(48.8%) 41(66.6%) 40(64.5%)
Male 22(48.9%) 31(68.9%) 30(66.7%)
Female   8(47.0%) 10(58.8%) 10(58.9%)
25-29.9 Total     4(6.5%)  8(12.9%) 11(17.7%)
Male     3(6.7%)  5(11.1%)   6(13.3%)
Female        1(6%)  3(17.7%)   5(29.3%)
DEXA Fat: There is statistically significant increase in the fat content (in gm) over a period of 6 months in 
all  the sub regions of the body except  the head fat.  However the head fat  gain significant  in females 
(p=0.04). Over a period of 6 months, the arm fat 
Increased by 37.4%, and increment  was 378.7gm in males vs. 912.4gm in females, trunk  fat increment 
was 36.6 %, with increment of 1753.8 gm in males vs. 2480.1 gm in females and leg fat increment was 
889.4gms in males  vs. 1716.4 gm in females with total increment of 31.6%.
Figure 5. Temproal profile of Total Body and regional fat
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Table 7. Body fat composition changes with time
Fat
(Gms)
Baseline
(Mean±SD)
3 months
(Mean±SD)
6 months
(Mean±SD)
p
Head 861.17±104.45 888.79±108.53 881.49±148.81 0.21
Trunk 5336.13±3319.64 7057.28±3233.09 7291.84±3491.24 <0.01
Arms 1268.21±818.97 1626.80±868.43 1743.92±1015.75 <0.01
Legs 3524.28±1814.22 4394.70±1966.65 4640.43±2027.97 <0.01
Total body 11178.55±5787.04 13961.78±5761.53 14576.68±6205.24 <0.01
Table 8. Fat content for males and females with time
Fat (gm) Sex Baseline
(mean±SD)
3 months
(mean±SD)
6 months
(mean±SD)
p
Head Male 890.95±94.81 912.43±109.84 901.04±162.55 0.51
Female 782.33±88.18 826.20±77.43 829.73±88.56 0.04
Trunk Male 4873.81±3071.40 6580.21±3083.49 6627.65±3241.60 <0.01
Female 6559.84±3725.51 8320.12±3371.99 9049.99±3612.14 <0.01
Arms Male 1094.54±691.22 1419.91±727.71 1473.27±822.04 <0.01
Female 1727.94±966.35 2174.44±989.90 2640.35±1150.60 <0.01
Legs Male 3024.32±1528.18 3840.55±1814.80 3913.73±1619.11 <0.01
Female 4847.68±1887.44 5861.58±1593.31 6564.07±1747.43 <0.01
Total Male 10203.69±5318.91 12747.12±5315.62 12919.64±5369.05 <0.01
Female 13759.05±6335.02 17177.05±5806.87 18962.96±6273.94 <0.01
Body fat in gm by Anthropometry & correlation with DEXA: 
The body fat as derived by anthropometric measurements at 3 time points is given in the table below. The 
intra class coefficient between the fat measured by anthropometry and to that of DEXA were 0.91, 0.93 & 
0.93   at  baseline,  3  months  and  at  6  months  (p<0.01)  showing  a  very  good  agreement  between 
anthropometric measurement of fat and  by DEXA. 
Table 9. Correlation between Anthropometry and DEXA fat measurements
Fat Baseline
(mean±SD)
3 mo
(mean±SD)
6 mo
(mean±SD)
Anthropometry (Kg) 10.42±5.92 13.42±5.91 14.76±6.76
DEXA (Kg) 11.17±5.78 13.96±5.78 14.57±6.20
ICC 0.91 0.93 0.93
Figure 6. Correlation between DEXA and Anthropometric Fat measurements at baseline
Figure 7. Correlation between DEXA and Anthropometric Fat measurements at 
(a) 3months and (b) 6 months
Bland Altman Analysis:
Table 10. Bias and Precision Analysis of Anthropometric Fat measurement to DEXA fat measurement
 Fat (Kg) Bias (Mean 
difference)
Precisio
n (SD)
Limits of  agreement
Baseline +0.751 2.14 -3.97 to 5.47
3 months +0.541 2.08 -3.56 to 4.64
6 months -0.186 2.40 -4.88 to 4.51
computed fat at baseline in Kg
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Figure 8 Bland Altman plots for fat measurement by anthropometry and DEXA at (a) baseline, (b) 3  
months and (c) 6 months
mean fat of DEXA and ANTRO at baseline
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mean fat of DEXA and ANTRO at 3 months
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The results of Bland Altman Analysis are given in the table above. The Limits of agreement  show that the 
anthropometry may be 3.97 kg lower or 5.47 kg higher than DEXA measured at baseline, 3.56 kg  & 4.88 
kg lower or 4.64 kg & 4.51 kg  higher at 3 months and 6 months respectively.
Fat Percentage: 
Parallel to fat in gm, fat in percentage increased over time significantly except head (p<0.01) and between 
sex, it followed similar pattern of fat in gm. 
Table 11. Temporal profile of total and regional fat percentages
Fat % Baseline
(Mean±SD)
3 months
(Mean±SD)
6 months
(Mean±SD)
p
Head 18.53±0.80 18.77±0.67 18.81±0.55 0.18
Trunk 20.65±9.30 24.93±8.34 25.34±8.91 <0.01
Arms 21.33±11.14 25.93±10.90 26.85±12.03 <0.01
Legs 21.90±9.37 24.78±8.62 25.57±9.62 <0.01
Total body 20.97±8.44 24.53±7.84 25.11±8.54 <0.01
Table 12. Temporal profile of total and regional fat percentages in males and females
Fat % Sex Baseline
(Mean±SD)
3 months
(Mean±SD)
6 months
(Mean±SD)
p
Head Male 18.58±.92 18.78±.74 18.78±.59 0.21
Female 18.38±.33 18.74±.42 18.88±.42 <0.01
Trunk Male 18.32±7.76 22.46±7.00 22.47±7.39 <0.01
Female 26.81±10.56 31.47±8.25 32.94±8.24 0.001
Arms Male 17.45±7.86 21.68±7.85 21.75±8.52 <0.01
Female 31.59±12.20 37.21±9.86 40.36±9.23 <0.01
Legs Male 17.91±6.11 21.07±6.24 21.02±6.14 <0.01
Female 32.45±8.33 34.62±5.87 37.62±6.03 <0.01
Total fat Male 18.17±6.42 21.55±6.00 21.68±6.32 <0.01
Female 28.39±8.80 32.42±6.64 34.20±6.86 0.001
Body fat in percentage by Anthropometry & correlation with DEXA: 
The body fat % as derived by anthropometric measurements at 3 time points is given in the table below. 
The intra class coefficient between the fat % measured by anthropometry  and to that of DEXA were 0.88, 
0.92,  & 0.91  (p<0.01)  at  baseline,  3  months  and 6  months  showing a  very  good agreement  between 
anthropometry and DEXA with respect to fat in percentage
Table 13. Correlation between Anthropometry and DEXA fat percentage measurements
Table 14. Bias and Precision analysis for fat percentage by Anthropometry and DEXA
Fat
Baseline
(Mean±SD)
3 months
(Mean±SD)
6 months
(Mean±SD)
Anthropometry fat (%) 18.99±8.54 23.10±8.22 24.93±9/30
DEXA fat (%) 20.97±8.44 24.53±7.84 25.11±8.54
ICC 0.88 0.92 0.91
p <0.01 <0.01 <0.01
 Fat % Bias (mean
 difference)
Precision 
(SD)
Limits of
 agreement
Baseline 1.98 4.14 -6.13 to 10.09
3 months 1.42 3.12 -4.69 to 7.53
6 months 0.59 3.66 -6.58 to 7.76
Mean fat percentage of Dexa and Anthro at baseline
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Figure 9. Bland Altman Plot for fat % by anthropometry and DEXA at baseline
Figure 9. Bland Altman Plot for fat % by anthropometry and DEXA at (a) 3months and (b) 6 months
The results of Bland Altman Analysis are given in the table above. The 
Limits of agreement  show that the anthropometry may be 6.13% lower or 10.09% higher than DEXA 
measured  at  baseline,  4.69%  & 6.58% lower  or  7.53% & 7.76%  higher  at  3 months and 6 months 
respectively.
Bone mineral content: 
There is overall decrease in the bone mineral content in all the sub regions of the body, but significant in 
the regions of trunk (3.8%), spine (6.7%) and pelvis (6.9%) and the whole body (3.5%). Males tend to have 
more reduction in the bone mineral content compared to females.
Table 15. Temporal profile of Bone Mineral Content
BMC Baseline 3 months 6 months p
Mean Fat% of Dexa and Anthro at 3 months
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(Mean±SD) (Mean±SD) (Mean±SD)
Arms 271.94±55.68 264.87±60.13 265.26±60.39 0.07
Ribs 145.48±35.91 150.49±36.10 148.51±35.47 0.17
Trunk 468.35±91.39 454.42±90.39 450.17±90.00 0.01
Spine 147.37±25.63 138.76±25.68 137.34±24.68 <0.01
Pelvis 176.10±43.49 165.16±38.50 163.82±41.54 <0.01
Legs 693.68±148.94 688.26±144.03 686.06±138.21 0.39
Total body 1928.62±344.73 1873.87±314.13 1859.97±310.15 0.01
Table 16. Temporal profile of Bone mineral content in males and females
BMC Sex Baseline 
(Mean±SD) 
3 months
(Mean±SD) 
6 months
(Mean±SD) 
p
Arms Male 292.23±47.82 289.18±50.27 288.69±52.06 0.40
Female 218.24±36.20 200.52±27.81 203.23±28.58 0.14
Ribs Male 155.27±34.57 161.14±34.02 156.16±36.51 0.18
Female 119.57±25.45 122.29±24.93 128.25±23.05 0.03
Trunk Male 492.83±88.81 477.76±89.33 468.69±93.04 0.01
Female 403.58±63.30 392.64±60.15 401.14±59.66 0.26
spine Male 151.67±25.85 142.91±26.21 139.45±25.92 <0.01
Female 135.99±21.85 127.79±21.19 131.76±20.72 0.07
Legs Male 745.85±135.23 738.38±133.81 732.46±129.61 0.20
Female 555.59±79.80 555.57±63.86 563.24±67.41 0.60
pelvis Male 186.72±44.12 173.70±39.38 172.42±42.73 <0.01
Female 148.00±26.49 142.55±25.26 141.07±28.29 0.15
Total Male 2036.99±321.99 1973.56±295.01 1949.19±301.68 0.02
Female 1641.74±217.92 1609.99±186.94 1633.79±186.57 0.04
Bone mineral density: The bone mineral density significantly decreased in all the sub regions of the body 
except pelvis. Males had significant  reduction in the BMD (p<0.01) as compared to females except in 
pelvis.
Table 17.Temproal Profile of Bone Mineral Density
BMD
(g/cm2)
Baseline
(Mean±SD) 
3 months
(Mean±SD)
6 months
(Mean±SD)
p % loss
Arms 1.46±0.14 1.45±0.13 1.44±0.13 <0.01 1.36
Ribs 1.28±0.17 1.26±0.15 1.24±0.15 <0.01 3.12
Spine 1.79±0.20 1.72±0.20 1.70±0.25 <0.01 5.02
Pelvis 0.96±0.12 0.95±0.12 0.94±0.12 0.14 2.08
Legs 2.23±0.27 2.18±0.25 2.15±0.24 <0.01 3.58
Total body 1.06±0.09 1.03±0.08 1.02±0.08 <0.01 3.77
Table 18. Temporal profile of bone mineral density in males and females
BMD (g/cm2) Sex Baseline 3 months 6 months p
Arms Male 1.52±0.11 1.51±0.10 1.49±0.11 <0.01
Female 1.31±0.07 1.30±0.07 1.29±0.06 0.46
Ribs Male 1.32±0.16 1.30±0.15 1.27±0.16 <0.01
Female 1.16±0.12 1.16±0.09 1.16±0.10 0.84
spine Male 1.80±0.20 1.72±0.19 1.69±.21 <0.01
Female 1.72±0.19 1.72±0.24 1.73±0.33 0.67
Legs Male 2.32±0.24 2.26±0.24 2.22±0.23 <0.01
Female 2.00±0.18 1.96±0.13 1.95±0.15 0.06
pelvis Male 0.95±0.12 0.94±0.12 0.94±0.12 0.18
Female 0.96±0.13 0.96±0.13 0.95±0.12 0.57
Total Male 1.07±0.87 1.05±0.08 1.03±0.08 <0.01
Female 1.02±0.90 1.00±0.07 0.99±0.80 <0.01
Lean body weight: 
There  was  overall  increase  in  the  lean  body weight  (p=0.01)  and  legs  in  particular  (p<0.01).  Similar 
findings were  seen between the sub category of males and females.
Table 19. Temporal profile of Lean Body Weight
Lean (gms) Baseline 3 months 6 months p
Arms 4156.00±1072.69 4255.84 ±993.89 4292.30 ±1030.18 0.14
Legs 11833.29±2752.61 12456.22±2357.50 12570.69±2310.53 <0.01
Trunk 19553.29 ±3700.51 19775.16 ±3910.36 20144.51 ±3203.20 0.18
Head 3324.97±400.27 3388.31 ±378.97 3396.11 ±420.17 0.04
Total body 38921.78 ±7391.14 40241.09±6440.98 40403.58 ±6694.60 0.01
Table 20. Temporal profile of Lean Body Weight in males and females
Lean 
(gms)
Sex Baseline 3 months 6 months p
Arms Male 4631.58±851.84 4704.34±754.13 4722.97±840.99 0.55
Female 2897.12±267.30 3068.62±372.62 3152.27±445.58 0.03
Legs Male 12948.92±2308.44 13451.73±1915.95 13491.15±1915.95 0.006
Female 8880.15 ±1210.74 9821.05±963.77 10134.18±935.31 <0.01
Trunk Male 20860.46±3270.05 20853.09±3957.76 21285.56±2916.70 0.45
Female 16093.12±2296.63 16921.81±1817.35 17124.11±1539.03 0.02
Head Male 3450.30±354.81 3490.38±369.15 3504.16±415.52 0.31
Female 2993.24±321.76 3118.14±256.78 3110.10±280.20 0.11
Total
lean
Male 41905.93±6217.45 43003.22±5125.67 43001.65±5882.86 0.04
Female 31022.55±3259.37 32929.58±2767.67 33526.35±2541.43 <0.01
Lean body weight (LBW) by Anthropometry & correlation with DEXA:
The lean body weight derived from weight of the individual by James equation at 3 time points are given in 
the table below.  The James equation overestimates LBW by 12.28%, 12.97% and 13.82% at baseline, 3 
months and 6 months respectively. The intra class coefficient between anthropometric measurement of lean 
body weight and DEXA were 0.88, 0.90 & 0.88 at baseline, 3 months and 6 months respectively (p<0.01), 
showing a good agreement between anthropometric lean and DEXA lean.
Table 21. Correlation between lean mass measurement by Anthropometry and DEXA
 Lean body weight Baseline
(Mean±SD)
3 months
(Mean±SD)
6 months
(Mean±SD)
Computed Lean body weight (Kg) 43.70 ± 6.95 46.24 ± 6.89 46.88 ± 6.68
DEXA lean body weight (Kg) 38.92 ± 7.39 40.24 ± 6.44 40.40 ± 6.69
ICC 0.88 0.90 0.88
p <0.01 <0.01 <0.01
Dexa lean in kg at baseline
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Figure 11. Correlation between Lean mass by Anthropometry and DEXA at basleine
Figure 12. Correlation between Lean mass by anthropometry and DEXA at (a) 3 months and (b) 6 
months.
Bland Altman analysis: The results of Bland Altman Analysis are given in the table below. The Limits of 
agreement show that DEXA may be 11.60 kg lower or 2.04 kg higher than anthropometry measured at 
baseline,  0.41kg  to  11.58kg  lower  at  3months  and  0.12kg  to  12.83  kg  lower  than  anthropometric 
measurements at 6 months. Thus anthropometry overestimates lean body weight in Indian population.
Table 22. Bias and Precision analysis for Lean mass by Anthropometry and DEXA
 Lean body (Kg) Bias (Mean 
difference)
Precision (SD) Limits of
 agreement
Baseline -4.78 3.48 2.04 to -11.60
3 months -6.00 2.85 -0.41 to -11.58
6 months -6.48 3.24 -0.12 to -12.83
Dexa lean in Kg at 3 months
6050403020
co
m
pu
te
d 
le
an
 b
od
y 
w
t a
t 3
 m
on
th
s
70
60
50
40
30
Dexa lean in Kg at 6 months
6050403020
co
m
pu
te
d 
le
an
 b
od
y 
w
t a
t 6
 m
on
th
s
70
60
50
40
30
a b
Figure 13. Bland Altman plots for lean mass by  Anthropometry and DEXA at 
(a) baseline, (b) 3 months and (c) 6 months
Mean lean for the Anthro and Dexa scores at Baseline
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Mean lean of the Anthro and Dexa scores at 3 months
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Mean values of Anthro and Dexa at 6 months
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Leptin: 
The mean leptin levels increased from 5.28ng/ml at baseline to 6.09ng/ml at 3 months to 15.48ng/ml at 6 
months. The females had higher level of leptin compared to males at all the points of time (8.5ng/ml vs 
4.07 ng/ml at baseline, 10.99ng/ml vs. 4.23ng/ml at 3 months and 31.30ng/ml vs. 9.50ng/ml at 6 months.) 
Table 23. Temporal Profile of Leptin levels
Leptin
ng/ml
Baseline
ng/ml
3 months
ng/ml
6 months
ng/ml
Male (n=45) 4.07±7.59 4.23±7.56 9.50±12.08
Female (n=17) 8.50±8.04 10.99±9.02 31.30±19.84
Total (n=62) 5.28±7.90 6.09±8.48 15.48±17.45
Correlation of leptin with body fat, bone mineral content (BMC), bone mineral density (BMD) and 
lean body mass:
The correlation of leptin with respect to fat in “gms” & percentage, bone mineral content and its density,  
lean body weight is given in the table below. Leptin has good correlation with respect to fat in gms (ICC 
being 0.65, 0.65 and 0.81 at baseline, 3 months and 6 months respectively) and fat percentage (ICC being 
0.61, 0.65 and 0.77 at baseline,  3 months and 6 months respectively.  Leptin has poor correlation with 
respect to bone mineral and lean body tissue. 
Table 24. Correlation between Leptin and Fat, BMC, BMD and lean mass by DEXA
Leptin  Total 
Fat (g)
Total 
Fat (%)
BMC
(g)
BMD
(g/cm2)
Lean
(g)
baseline r 0.65 0.61 -0.52 -0.05 -0.20
P <0.01 <0.10 0.68 0.66 0.87
3 months r 0.65 0.65 -0.08 -0.03 -0.17
P <0.01 <0.01 0.49 0.80 0.16
6 months r 0.81 0.77 -0.05 -0.03 -0.18
p <0.01 <0.01 0.66 0.79 0.14
Figure 14. Correlation between Leptin and Body fat at (a) baseline, (b) 3 months and (c) 6 months
DISCUSSION
In our study, we assessed the change in body composition over a period of 6 months using DEXA with 
respect to body fat, bone mineral content, bone mineral density and lean body mass. In addition, agreement 
between  measurements  made by anthropometry and  DEXA for  the body fat  and lean  body mass  was 
evaluated. Finally, the correlation of leptin with body fat, bone mineral and lean body mass was analyzed.
Weight Gain: There is progressive weight gain in both genders during the first 6 months. Nearly half of 
the study populations were underweight immediately after renal transplantation. However, 66% of patients 
had normal BMI at 3 and 6 months. Only 12.9% and 17.7% of patients were over weight at 3 and 6 months 
respectively.  Females tend to gain weight  more than males over a period of time and were more over 
weight.
leptin (ng/mi) at baseline
403020100
To
ta
l f
at
 (g
m
s)
 a
t b
as
el
in
e
30000
20000
10000
0
leptin  (ng/ml) 3 months
403020100
 T
ot
al
 fa
t (
 g
m
s)
 a
t 3
m
on
th
s
30000
20000
10000
0
leptin (ng/ml) at 6 months
100806040200-20
To
ta
tl 
fa
t (
gm
s)
 a
t 6
 m
on
th
s
30000
20000
10000
0
b c
a
 In the study by Cofana et al 89, 38% of the patients were over weight and 16% were obese. Obesity was 
more prevalent  in women (21% vs 13%). In  our study however,  only 12.9% of the patients were over 
weight and most often they were women (6.0% vs 6.7% at baseline, 17.7% vs 11.1% at 3 months and 
29.3% vs 13.3% at  6  months).  Males  had attained their  near  maximal  weight  by 3 months,  whereas, 
females continued to gain weight till 6 months 
Fat Gain: There is significant increase in the total & regional fat over a period of 6 months except for the 
head fat. Patients tend to accumulate more fat in arms and trunk. 
In the study by Kooman et al 90, weight gain observed in the first few months after renal transplantation is 
predominantly due to an increase in body fat mass, the changes in truncal fat mass being most pronounced. 
This was consistent with finings in our study. 
DEXA has been validated for the assessment of the fat, however it is expensive. Skin fold thickness is a 
well-established,  simple  and  inexpensive  technique  for  determining  body  fat  in  normal  adults.  In  the 
present study, we wanted to assess the validity of anthropometric measurements as compared to DEXA in 
renal allograft recipients.  Anthropometry underestimated fat content at baseline and 3 months (mean bias 
of -0.75 and 0.55 kg respectively). However, it overestimated fat content at 6 months compared to DEXA 
(mean bias  of  -0.19Kg).  These differences  are negligible  in the clinical  situation concerned.  However, 
anthropometry consistently underestimated fat % measured by  DEXA (bias 4.69% to 10.09%).
In the study by Hart PD, et al 91. who analyzed 34 renal transplantation patients at time of transplantation, 
and again after 3 and 6 months, they found the ICC between DEXA and skin fold thickness were  0.84, 
0.78 & 0.85 respectively at (p<0.01). and in 34 control patients, the ICC was 0.95  (p<0.01) and skin fold 
measurements underestimated changes in the total body fat, especially those gaining substantial amounts of 
body fat. 
In our study, the correlations were good both with fat and fat %. Even though there are some discrepancies 
between skin fold thickness and DEXA, they appear to be minimal and hence skin fold thickness can be 
used as reliable measure of body fat.
Bone mineral: Renal  transplantation improves  the metabolic  environment  and restores  the glomerular 
filtration  and  renal  production  of  1,25-dihydroxy  vitamin  D3 which  is  impaired  during  chronic  renal 
failure, in spite of this bone loss is a frequent and well-known complication in the first months of after renal 
transplantation particularly at trabecular bone sites (92, 93). 
In our study, there is decrease in the bone mineral content of whole body in general and trunk, spine, pelvis 
in particular. Males tend to have more reduction. The bone mineral density however, reduced in all the sub 
regions except pelvis and maximal loss of BMD occurred in the spine.  In  the study by Fabio et al  93 
involving 20 males, the bone mineral density reduced only in ribs and pelvis. Hober et al  94 showed that 
baseline total body and compartmental BMD was approximately 9% lower than in controls; during the 5-
month  follow-up,  the  BMD  of  the  limbs  remained  unchanged,  where  as  that  of  the  trunk  and  head 
decreased.(3)
Kwan et al 95 found significant decrease of total body BMD (approximately 2.5%) at 3 months, followed by 
partial  recovery  at  6  months  with  significant  bone  loss  also  in  the  spine  and  femoral  neck  with  no 
subsequent recovery.
Further more Cuteo-Manzano et al 96. indicated male sex as one of the strongest predictive factors for low 
bone mass in long term renal transplantation 
Lean Mass: Muscle wasting is well known consequences of kidney transplantation and it  is related to 
glucocorticoid therapy. Mathieu et al  97. found a decrease in lean mass and increase in trunk fat mass in 
kidney recipients treated with immunosuppressive monotherapy (CsA). Steiger et al 98 found a decrease of 
approximately 10% in the limb and trunk lean mass in comparison with controls and, during the course of 
the follow-up, an increase in fat mass and limb lean mass in male patients; reduction in trunk lean mass 
observed during the first 2 months of follow-up and remained unchanged there after. Fabio et al 93 found no 
change  in  total  and sub regional  lean  mass.  Ham et  al  99 did  not  find any relationship between body 
composition and different steroid dosages.
Contrary to the decrease in the lean mass in the above studies, in our study, there was increase in lean mass 
in  general  and  legs  in  particular  (p  <  0.01).  In  addition,  arm  lean  mass  in  females  also  increased 
significantly (p = 0.03). This is probably due to increased physical activity following renal transplantation. 
James’s equation over estimated Lean body mass (mean bias -6.0 Kg)
Leptin: Leptin plays an important role in regulating appetite and energy expenditure and also functions in 
the  neuroendocrine,  hematopoietic,  and  immune  systems,  among  others.  Leptin  may  be  involved  in 
modulating bone mineralization. females tend to have more leptin as studied by Ostlund et al 100 .  Agras et 
al 101 showed elevated leptin level is associated with increased bone mass at lumbar sites in renal transplant 
recipients, suggesting its bone-sparing effect.
Serum Leptin levels correlated with the percentage of body fat, trunk fat, lean body mass, serum creatinine, 
and urea. It was not related to nutritional status, BMD, or bone metabolism in kidney allograft recipients as 
seen  in  study  by   Malyaszko  et  al.102 It  is  also  not  related  to  excretory  graft  function  and 
immunosuppression as shown by Franciszek et al. 103
In our study, the leptin increased over a period of time. Females had elevated leptin at all points of time. 
Leptin correlated with fat, but had no relationship to BMD or lean mass. 
Conclusions
In renal allograft recipients, 
1) There is significant weight gain after transplantation, more commonly in women and most often 
due to an increase in body fat (especially in arms and trunk)
2) The bone mineral content and density decreases with time, often in men and predominantly in the 
spine.
3) The lean body mass increases marginally with time, predominantly in the legs.
4) Skin fold thickness is a  reliable and valid measure of body fat
5) James equation overestimates lean body mass measured by DEXA.
6) Serum leptin level increased over a period of time predominantly in females.
7) Serum leptin levels correlate well with fat content, but not with BMD or lean mass. 
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Sex: M/F
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